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 DNA methylation is one of several epigenetic mechanisms used by cells to  
control gene expression. DNA methylation patterns are not randomly distributed, instead 
they are compartmentalized by region. In normal cells heterochromatin is 
hypermethylated and transcriptionally silent. The rest of the genome is predominantly 
CpG poor, except for CpG islands, which tend to be hypomethylated and associated with 
active genes. In tumors this normal compartmentalization is reversed. Cancers are 
characterized by global hypomethylation  that affects repetitive DNA found in 
heterochromatin, leading to genomic instability. Concurrently, site-specific 
hypermethylation of CpG islands at the promoters of tumor suppressor genes leads to 
silencing.  
 This work focused on how DNMT3B influences methylation patterns on a global 
and local scale. We hypothesized DNMT3B regulated DNA methylation outside of 
promoter regions. Using an isogenic colorectal cancer cell line panel we profiled global 
DNA methylation patterns across the genome in the presence and absence of DNMT3B. 
Upon DNMT3B removal there was a statistically significant loss of methylation in Gene 
Bodies, 3' UTRs, Shores, and Shelves. Interestingly, loss of DNMT3B had a greater 
effect on the methylation status of non-CpG island genes when compared to CpG island 
genes. Re-introduction of wild-type DNMT3B resulted in a gain of methylation in these 
areas. Unexpectedly, mutant DNMT3B also caused increased methylation, suggesting 
DNMT3A induction. This data supports the notion DNMT3B regulates DNA methylation 
in a context-dependent manner at distinct regions of the human genome. 
 Local studies identified endogenous target genes and demonstrated that DNMT3B 
is capable of modulating gene expression independently of its methyltransferase activity. 
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Both wild-type and catalytically dead DNMT3B repressed target genes to similar 
degrees, suggestive of protein-protein interactions at the N-terminus. A DNMT3B-
specific loss of methylation  may help to explain expression changes seen in non-CpG 
island genes. However, it was not required for gene repression at CpG island genes. 
Further studies in genetic knockout cells alluded to changes in chromatin status upon 
DNMT3B overexpression that explained transcriptional repression at this subset of genes, 
such as decreased enrichment for a histone modification associated with transcriptional 
activity (H3K4me3) and the recruitment of a repressive epigenetic protein (LSD1).  
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The definition of epigenetics 
 Conrad Hal Waddington first introduced the term "epigenetics" in a series of 
seminal work geared towards constructing an integrated view of biology. Waddington's 
definition stated "the branch of biology which studies the causal interactions between 
genes and their products, which bring the phenotype into being" [1]. As our 
understanding of epigenetics evolved, so did the meaning of the word. Our modern 
definition of epigenetics is the study of heritable changes (mitotic or meiotic) in gene 
function without a corresponding change in DNA sequence [2, 3]. Epigenetic 
mechanisms can be covalent or noncovalent alterations to DNA, RNA [4], or proteins [5, 
6]; including DNA methylation, histone modifications, non-coding RNA interactions, and 
changes in chromatin structure or architecture. One of the most well-characterized 
epigenetic mechanisms is DNA methylation, which is both a heritable and reversible 
process. 
Biological significance of DNA methylation 
 DNA methylation is a covalent biochemical modification that plays important 
biological roles in a variety of species, including fungi, plants, vertebrates, and humans. It 
occurs at the carbon 5 position of the cytosine ring. The multi-step enzymatic mechanism 
first involves binding to DNA and flipping the target sequence out of the double helix. 
Next, a transient covalent complex is formed. Finally, there is a transfer of the methyl 
group from the donor S-Adenosyl Methionine (SAM) to recipient DNA [7].  
 Proper DNA methylation patterning is required for many different biological 
processes, such as development [8], differentiation [8], regulation of gene expression [9], 
X-chromosome inactivation [10], genomic imprinting [11], and silencing of exogenous 
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retroviral DNA [12]. For example, DNA methylation is extensively reprogrammed during 
embryonic development. The paternal genome is actively demethylated soon after 
fertilization; while the maternal genome is passively demethylated after a failure to 
maintain methylation through early rounds of successive cell division. Cellular fate can 
also be determined by DNA methylation through the targeting of specific genes important 
for pluripotency and differentiation. Most importantly for this work, the presence of DNA 
methylation can regulate gene expression by strongly interfering with the ability of 
transcription factors to bind the promoter [13]. It is growing increasingly clear that 
dysregulation of DNA methylation plays an important role in the etiology of numerous 
diseases. Much of our understanding stems from knowledge of DNA methylation 
dynamics in cancer. 
DNA methylation and cancer 
 DNA methylation patterns are not randomly distributed throughout the genome. 
Instead they are compartmentalized by region. Heterochromatin, which contains 
centromeres, telomeres, and repetitive DNA sequences, tends to be hypermethylated and 
transcriptionally silent in normal cells. The rest of the genome is predominantly CpG-
poor and devoid of methylation. However, there are some CpG-rich regions. Such 
regions are found at promoters and contain a dense concentration of CpG dinucleotide 
clusters called CpG islands. Normally, DNA methylation is rare at CpG islands. These 
genomic features tend to be hypomethylated and associated with active genes. 
 In tumors, the normal compartmentalization is reversed. Aberrant DNA 
methylation patterns are frequently seen in cancer, both on a genome-wide scale and at 
specific genes [9]. Cancer cells are characterized by global hypomethylation, that 
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primarily affects repetitive DNA and leads to genomic instability, with concurrent site-
specific CpG island hypermethylation (Figure 1.1). Hypermethylation of tumor 
suppressor genes in the promoter region often leads to gene silencing. Since epigenetic 
events are reversible, these abnormal alterations are rich therapeutic targets. DNA 
methylation is currently being used as a tool for better cancer diagnosis, prognosis, and 
prediction to therapeutic response in the clinic [14]. A crucial step towards a better 
understanding of tumorigenesis is to demystify how tumors both acquire and maintain 
abnormal methylation patterns. These processes are mediated by DNA methyltransferases 
(DNMTs).  
Mammalian DNA methyltransferases 
 DNMTs are a family of enzymes that transfer a methyl group from SAM to the 
carbon 5 position of cytosine residues in DNA, which occur in CpG dinucleotides. Only 3 
out of 5 are enzymatically active. From a classical perspective, the active mammalian 
DNMTs have been assumed to fall into 2 broad functional categories, maintenance and 
de novo. DNMT1 has a preference for hemimethylated DNA (5-30%) and is localized to 
DNA replication [15]. Consequently, it is assigned the function of maintenance 
methylation. DNMT3A and DNMT3B show no preference for hemimethylated DNA 
[16] and are thought to establish new methylation patterns [17]. DNMT3L lacks a 
catalytic domain but complexes with and stimulates the activity of DNMT3A and 
DNMT3B [18, 19]. DNMT2 contains all of the conserved motifs shared by the other 
known DNMTs, but it does not perturb de novo or maintenance methylation. Instead, it is 
responsible for methylating a small RNA (aspartic acid tRNA) [20]. Misregulation of 
DNMTs have been attributed to tumorigenesis. For example, elevated Dnmt3b1 
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expression in the Apc
Min/+ 
mouse model has been shown to enhance colorectal 
carcinogenesis and cause methylation of tumor suppressor genes, leading to their 
silencing [21]. 
 Structurally, the enzymatically active DNMTs (DNMT1, DNMT3A, and 
DNMT3B) can be divided into 2 domains (Figure 1.2). The C-terminus of all three 
proteins contain a highly conserved catalytic motif, but the N-terminal region is not 
highly conserved. However, paralogous proteins DNMT3A and DNMT3B share a similar 
feature at the N-terminus. The PHD domain, also referred to as the ATRX-like domain, 
has been implicated in protein-protein interactions and is a common motif found in 
chromatin-associated proteins [22].  
DNA methyltransferases, transcription factors, and transcriptional repression 
 Mammalian gene expression is a complex process involving both transcriptional 
activators as well as repressors. The impact of genetic alterations on gene regulation has 
been well studied. As a field, epigenetics is adding to our repertoire of factors that control 
gene expression. DNA methylation at promoters functions to repress transcription and 
DNMTs are key epigenetic regulatory proteins implicated in this molecular mechanism.  
 Interactions between DNMTs and transcription factors have been proposed to 
target specific promoters for methylation. Thus, both overlapping and distinct DNMT 
targeting can be expected. DNMT3B, but not DNMT1,  has been shown to regulate 
specific genes in human cancers [23-25]. Although DNA methylation prevents their 
promoter binding, some transcription factors are known to recruit DNMT3B [26, 27]  or 
directly interact with the protein [4, 28]. This evidence suggests DNMT3B has distinct 
endogenous targets on which it exerts its transcriptonal regulatory effects. 
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DNA methyltransferases, chromatin modifications, and transcriptional repression 
 Chromatin is the complex of DNA and histone proteins that act as a molecular 
scaffold for the packaging of our genome. Histones are a family of basic proteins which 
wrap around negatively charged DNA. H1 is a non-core histone that interacts with linker 
DNA between histones. Other histones are found in octamer cores containing two copies 
each of H2A, H2B, H3, and H4. Histone methylation occurs at lysine (K) and arginine 
(R) residues of N-terminal tails that extend from the histone core. They may be mono-, 
di-, or trimethylated, with variable functionality according to the number of methyl 
groups.  
 Many studies have shown when the trimethylation of lysine 4 in the histone H3 
core (H3K4me3) is localized to promoter regions it correlates with transcriptional 
activation [29]. Conversely, the methylation of other histone marks have been associated 
with transcriptional repression. H3K9me3 is associated with transcriptional silencing and 
heterochromatin formation [30]. Clearly, histone methylation is a context-dependent 
modification that promotes variable transcriptional effects. Unlike methylation, histone 
acetylation is obligately linked to transcriptional activation and can be found both on the 
N-terminal tails and histone core. Acetyl groups add negative charge to positively 
charged lysines, thus reducing the interactions between DNA and histones. This opening 
of the tightly packed nucleosome allows transcriptional machinery access to the DNA 
and facilitates gene transcription.  
 Polycomb repressive complexes (PRC) remodel chromatin and can also 
contribute to a repressive chromatin state. EZH2, a catalytic component of PRC2, can 
catalyze trimethylation of lysine 27 of histone H3 (H3K27me3) [31]. H3K27me3 can 
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also recruit PRC1, the maintenance complex. How PRCs are recruited to gene targets 
remain unclear. Some work suggests the involvement of DNMT3B. DNMT3B1 has been 
associated with genes that harbor repressive H3K27me3 modifications and transcriptional 
inactivity [32]. Other studies show Dnmt3b preferentially interacts with nucleosomal 
DNA and higher-ordered chromatin as opposed to naked DNA [33, 34]. Dnmt3b, but not 
Dnmt3a, associated with linker histone H1 without enrichment of silent chromatin marks 
[34]. These results suggest Dnmts differentially interact with higher order chromatin. 
 Dynamic cross talk between DNA methylation and histone modifications occur in 
different cellular contexts. Some evidence suggests genomic methylation depends on 
histone methylation. In Neurospora crassa, H3K9 replacement and removal of the H3K9 
methyltransferase (DIM5) resulted in a loss of DNA methylation [35]. In mouse ES cells, 
H3K9 methyltransferase deficiency (Suv39h1 and Suv39h2) correlates with 
hypomethylation at repeat elements [36]. In addition, Suv39h has been shown to direct 
H3K9me3 at pericentromeric repeats, regions known to be controlled by Dnmt3b. G9a, 
another H3K9 methyltransferase, can promote DNA methylation independently of its 
enzymatic activity [37], possibly through interactions with DNMT1 [38]. Presumably, 
DNA methylation acts downstream from repressive marks like H3K9 methylation. 
 Chromatin structure can also regulate transcription by controlling what DNA-
binding factors have access to chromatin [39-41]. In addition to histone modifications, 
nucleosome positioning and turnover, and chromatin remodeling factors all determine 
chromatin structure. The cumulative effect of the DNA methylation and chromatin 




Functions of DNMT3B in Development and Disease 
 The strongest evidence supporting the biological importance of DNMT3s in 
establishing DNA methylation patterns comes from studies of early mouse development. 
After fertilization zygotes undergo active demethylation of the paternal genome, followed 
by genome-wide remethylation carried out by de novo methyltransferases [42, 43]. Work 
in single mutant ES cells lacking  Dnmt3a or Dnmt3b were still able to actively methylate 
proviral DNA after a new retroviral infection. However, double mutant ES cells were 
completely devoid of de novo methylation activity, suggesting both Dnmt3a and Dnmt3b 




 mice developed to term and appeared normal at birth, they 
succumbed by 4 weeks of age. By contrast, Dnmt3b
-/-
 mice were unviable at birth. It 





  mice display a different developmental phenotype suggests 
the two proteins may also have distinct functional properties. This notion is supported by 
ICF syndrome, a rare human disease characterized by DNMT3B deficiency [44].  
 ICF is the only human disease attributed to a genetic mutation in a DNA 
methyltransferase. With the loss of DNMT3B, non-coding repetitive sequences and genes 
located in constitutive and facultative heterochromatin are routinely hypomethylated in 
ICF cells [45]. This hypomethylation is associated with chromatin decondensation and 





Thesis goal and specific aims 
 Dnmt3b has been shown to be downregulated upon differentiation and expressed 
at low levels in adult somatic tissues [17]. Several studies have reported either 
overexpression or variant expression of DNMT3B in a variety of cancers, suggesting a 
role for the protein in tumorigenesis [46-48]. Contrary to its canonical de novo 
methylation role, a series of experiments using DNMT genetic knockout cell lines 
suggest DNMT1 and DNMT3B cooperate to maintain methylation in human cancers 
[49]. This study focused on how DNMT3B-specific methylation changes correlated with 
gene expression and/or chromatin changes.  
 Our lab was amongst the first to show the N-terminal domains of Dnmt3a and 
Dnmt3b alone can repress transcription of exogenous reporter genes [50]. This domain 
specific repression is partially mediated by HDACs, histone modifying enzymes known 
to promote transcriptional inactivity [50, 51]. One drawback to such studies is the 
inability to capture how truncated proteins change 3-dimensional structure, and by 
extension the potential disruption of important protein-protein interactions which may 
concurrently play a role in gene regulation. Also, reporter gene activity may not 
accurately reflect what happens in an endogenous setting due to a lack of other regulatory 
factors normally present in the cell.  
 This work sought to shed light on how DNMT3B-mediated DNA methylation 
targets methylation both genome-wide and at specific genes. Furthermore, we looked at 
the protein's role in regulating specific genes independently from its methyltransferase 
activity. We address shortcomings in previous studies by introducing a point mutation in 
a key residue critical for catalysis, which maintained the structural integrity of the 
10 
 
DNMT3B protein but also abolished all catalytic activity. Additionally, analyses were 
done exclusively on endogenous DNMT3B target genes. 
Aim 1: Identify differentially methylated genomic regions controlled by DNMT3B. 
 O'Hagan et al has shown DNMT3B complexes with DNMT1 and PRC4 upon 
oxidative damage. Interestingly, this complex relocalized from nonCpG-rich regions to 
CpG island promoters upon hydrogen peroxide treatment [52]. High expression genes 
were characterized by changes in histone marks and nascent transcription, while low 
expression genes gained DNA methylation. In another report, the genetic deletion of 
DNMT3B resulted in a 3% decrease in global methylation [49]. From our understanding 
of DNMT3B biology, it can be expected these changes occur at repetitive DNA 
sequences. However, this has never been confirmed. Technical limitations prevented 
deeper probing as to what specific genomic regions experienced this subtle loss. Both 
studies raise interesting questions about where DNMT3B is normally localized, its 
cancer-specific localization, and protein's role in initiating or maintaining methylation 
patterns across genomic regions. We used an Infinium 450K methylation array to analyze 
and further refine genome wide methylation patterns in cells both lacking and possessing 
DNMT3B. 
Aim 2: Elucidate mechanisms responsible for gene repression at DNMT3B gene 
targets. 
 Recent work from our group has shown DNMT1 can modulate gene expression 
without its catalytic activity, partially through its interactions with histone-modifying 
enzymes [53]. Clements et al. identified endogenous DNMT1 target genes and proved the 
protein represses target genes independent of its catalytic activity. Interestingly, DNA 
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methylation was not required for gene repression of the identified targets. When querying 
the chromatin status, active chromatin marks were depleted in the presence of either a 
wild type or mutant DNMT1 after recruitment to gene promoters. Repressive chromatin 
marks remained unchanged with the loss of DNMT1 alone at the target genes. By 
contrast, little is known about discrete genes under the exclusive control of DNMT3B. 
We identified endogenous targets and assessed their methylation and chromatin status to 
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Figure 1.1. DNA methylation patterns in normal and cancer cells. (Top panel) 
Normal cells are characterized by hypomethylated CpG island promoters at tumor 
suppressor genes. Exceptions include, germline-specific, tissue-specific, and imprinted 
genes which can possess extensive amounts of promoter methylation. Repetitive 
sequences are highly methylated to prevent active transcription. (Bottom panel) Cancer 
cells have aberrant DNA methylation patterns. CpG island promoters gain 
hypermethylation and the rest of the genome is globally hypomethylated, including 
previously hypermethylated gene regulatory regions and repetitive sequences. 
Hypomethylated repetitive sequences in cancer lead to the characteristic genomic 







Adapted from: Subramaniam, D., DNA methyltransferases: A novel target for prevention 
and therapy. Frontiers in Oncology, 2014. 4(80): p. 1-13.  
Figure 1.2. DNA methyltransferase protein domains. The N-terminus contains 
domains that interact with DNA and facilitate protein-protein interactions. The C-
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DNMT3B regulates DNA methylation in a context-dependent 





 DNA methylation is a well-studied epigenetic modification important for normal 
development and dysregulated in a variety of diseases. Cancer is characterized by global 
hypomethylation and hypermethylation of tumor suppressor genes. DNA methylation 
dynamics are regulated by the DNMTs (DNMT1, DNMT3A, and DNMT3B). The de 
novo methyltransferase, DNMT3B, has been implicated in the etiology of various 
diseases, including cancer. Classic studies suggested DNMT3B only localized to gene 
promoters. However, recent reports show it can also bind to gene bodies. Profiling DNA 
methylation patterns across the genome in the presence and absence of DNMT3B will 
provide novel insights into the functional role of this protein. In this study, an isogenic 
colorectal cancer cell line panel was subjected to an epigenome-wide scan using the 
Infinium HumanMethylation450 BeadChip platform, followed by gene expression 
analysis. 
 When DNMT3B is removed there is a loss of methylation across the genome, 
with the greatest change occurring in Gene Bodies, 3' UTRs, Shores, and Shelves. These 
methylation changes are subtle, yet significant (according to two-tailed paired t-tests). 
Interestingly, loss of DNMT3B has a greater effect on the methylation status of non-CpG 
island genes than CpG island containing genes. Expression changes displayed a bimodal 
distribution of correlation with methylation status at both promoters and gene bodies. 
Suggesting DNMT3B may work in concert with other proteins at discrete genomic 
regions to elicit transcriptional changes. Collectively, these data represent novel insights 
into the potential regulatory role of DNMT3B on DNA methylation at non-promoter 




 DNA methylation is one of the most well-studied epigenetic modifications [1]. It 
is responsible for normal development in a variety of species and dysregulated in many 
diseases [2]. Cancer cells are characterized by global hypomethylation with region-
specific hypermethylation at CpG island promoters of particular genes [3]. Most studies 
have focused on how DNA methylation at gene promoters function to repress 
transcription [4]. By contrast, the relationship of CpG methylation at other genomic 
regions to transcription is less well understood.  
 Definitively elucidating the function of gene body methylation is an area of strong 
interest and active investigation [5, 6]. Gene body methylation is widespread in 
eukaryotes and has been implicated in transcriptional elongation, silencing of repetitive 
DNA in intragenic regions, regulating alternative splicing and alternative promoter usage, 
as well as regulating insulators and enhancers [6]. The exact functional consequences 
warrant further study. Genome-wide methylation and expression data suggest gene body 
methylation is evolutionarily conserved and correlated with transcriptional activity [5, 7]. 
Mechanistically, a DNMT3 family member has been shown to antagonize Polycomb 
repression at gene bodies and promote an active chromatin state [8]. 
 Interestingly, DNA methylation in honeybees occurs primarily at gene bodies [9, 
10] and is regulated by DNA methyltransferase 3 (dnmt3) [11, 12], the orthologous 
protein to the de novo DNA methyltransferase 3B (DNMT3B) in humans. In cells from 
patients with immunodeficiency, centromeric region instability, facial anomalies (ICF) 
syndrome, a disease characterized by DNMT3B mutations, hypermethylation of active 
gene bodies is severely disrupted [13-15]. In human cancers, DNMT3B has been shown 
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to function as a transcriptional repressor [16-20] and may be responsible for the 
activation of tissue-specific programs that lead to early tumor formation [21].   
 We used an isogenic colorectal cancer cell line model genetically devoid of 
DNMT3B [22] to test the hypothesis that DNMT3B may regulate DNA methylation at 
non-promoter regions of the human genome. This study is the first of its kind to 
investigate the functional consequences of the removal and re-introduction of both wild 




Materials and Methods 
Cell culture  
HCT116, DNMT1
-/- 
hypomorph subclone 5F (MT1KO), DNMT3B
-/-





 subclone 2 (DKO) were previously described [22, 
23]. All cell lines were cultured in McCoy's 5A (Iwakata & Grace Modification) (Cat No. 
10-050-CV, Corning cellgro) supplemented with 10% fetal bovine serum (Cat No. 35-
011-CV, Corning cellgro) at 37 °C and 5% CO2 atmosphere. 
Plasmid constructs 
Wild type DNMT3B Isoform 1 (NM_006892.3) with N-terminal HA tag inserts were 
subcloned into a pEF1α IRES-puro vector (WT3B). A QuikChange II Site-Directed 
Mutagenesis Kit (Cat No. 200523, Agilent) was used to generate a catalytically inactive  




 subclone 2 (3BKO) cell line was transiently transfected for 48 hours with 
1 µg of both wild type and mutant plasmid DNA using Lipofectamine 2000 (Cat No. 
11668-027, Life Technologies). 
Western blot analysis 
Nuclear isolations were performed by resuspending cell pellets in CEBN with protein 
inhibitors and incubating on ice for 10 minutes, while vortexing every minute. After 
centrifugation the supernatant containing cytoplasmic fraction was saved for later use and 
nuclear pellets were washed in CEB with protein inhibitors. Nuclear pellets were 
resuspended in modified RIPA buffer with protein inhibitors, spermine, and spermidine, 
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followed by sonication and BCA assay. Anti β-actin (Cat No. A5441, Sigma-Aldrich) 
and anti HA-HRP (Cat No. H6533, Sigma-Aldrich) antibodies were used for analysis.  
Genomic DNA isolation 
DNeasy Blood and Tissue Kit™ (Cat No. 69504, Qiagen) was used to extract 1 µg 
genomic DNA from each cell line according to manufacturer's protocol. Isolated genomic 
DNA was bisulfite converted using EZ-DNA Methylation™ Kit (Cat No. D5001, Zymo 
Research).   
Methylation analysis with the Infinium HumanMethylation450 BeadChip Kit  
DNA methylation analyses of the 9 experimental samples (biological triplicates of 
3BKO, 3BKO overexpressing WT3B, and overexpressing MUT3B) and 3 control cell 
lines (HCT116, MT1KO, and DKO) were performed with the Infinium 
HumanMethylation450 BeadChip Kit (Cat. No. WG-314-1001, Illumina) according to 
the manufacturer’s protocols. The platform contains 486,428 CpG sites distributed across 
the promoter, 5′ UTR, TSS, first exon, gene body, 3′ UTR, CpG island, shore, and shelf 
regions and covers 99% of RefSeq genes [24].  
Methylation data processing and visualization 
Illumina GenomeStudio Methylation Module software (Part No. 11319130 Rev. B, 
Illumina) was used to calculate methylation levels and identify methylation signatures 
across the entire genome. Reported β-values reflect the estimated methylation level of 
each CpG locus using the ratio of intensities between methylated and unmethylated 
probes. The Bioconductor package in the R programming and software environment was 





RNeasy Mini Kit™ (Cat No. 74104, Qiagen) was used to extract 1 µg total RNA from 
each cell line according to manufacturer's protocol. Isolated total RNA was treated with 
RNase-Free DNase I (Cat No. 79254, Qiagen).   
Gene expression analysis with human gene expression microarrays 
Total RNA was hybridized to Human GE 4x44K v2 Microarray (Cat. No. G4845A, 
Agilent) according to manufacturer's protocol. 
Expression data processing and visualization 
The Bioconductor and Limma packages in the R programming and software environment 
were used to further analyze and visualize expression data. Log2 ratios were calculated. 





Global DNA methylation patterns upon DNMT3B removal and re-introduction 
 We first tested DNA constructs to ensure robust overexpression of both wild type 
and mutant DNMT3B. A point mutation was introduced into the C-terminal domain of 
DNMT3B, causing a Cysteine to Tryptophan substitution at residue 651. This residue is 
critical for catalysis and abolishes all catalytic activity without a change in 3-dimensional 
structure [25]. Western blot analysis indicates cells express the two exogenous DNMT3B 
species to similar degrees, independent of DNMT3B mutation status (Figure 2.1).  
 Next, Infinium 450K arrays were used as an epigenome-wide scan to assess the 
methylation status of various genomic signatures (TSS, 5' UTR, Promoter, Gene Body, 3' 
UTR, CpG Island, Shore, and Shelf) (Figure 2.2). Parental HCT116 is the most 
hypermethylated (β values 0.5) cell line used in this study and DKO is the least 
methylation (β values 0.5). Kernel density plots of the methylation data revealed 
changes in "promoter-associated" regions were minimal (Figure 2.3 A-C, F). In TSS 
(TSS1500 and TSS200), 5' UTR, Promoter (manually defined as CpGs found in -500 to + 
1500 with respect to the TSS), and CpG Island regions most β values failed to surpass a 
density of 4.0 in HCT116, reflecting little methylation. Most of the β values were 0.2. 
Low basal methylation in the parental line explains the failure to detect appreciable loss 
of methylation at these "promoter-associated" signatures in the 3BKO cells.  
 Comparatively, "non-promoter associated" regions like Gene Body and 3' UTR 
regions were more densely methylated in HCT116 and displayed decreased methylation 
in the absence of DNMT3B (Figure 2.3 D-E). Shores and shelves are flanking regions a 
significant distance away from CpG Islands, 2 kb and 4 kb respectively (Figure 2.2). 
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These regions also appeared to lose DNA methylation (Figure 2.3 G-H). Thus, DNA 
methylation appears to be more prominent and readily lost in the areas where 
transcription is not usually initiated (Gene Body, 3' UTR, Shore, and Shelf regions). 
Overexpression of both the wild type and mutant DNMT3B caused a gain of methylation 
in these regions. This was surprising since the mutant DNMT3B protein has no ability to 
perform its canonical de novo methyltransferase function. It is possible a compensatory 
mechanism in the overexpressed cell lines may involve the induction of DNMT3A, the 
other DNMT3 family member.  
Differentially methylated regions 
 In an effort to determine the statistical significance of the loss of DNA 
methylation in particular regions, all Gene Body, 3' UTR, Shore, and Shelf probes with a 
β-value of  ≥0.75 in HCT116 were selected. The 0.75-1.0 range appeared to correspond 
with the most demethylation in the kernel density plots (Figure2.3 D-E, G-H). Probes in 
the same position in 3BKO cells were compared while MT1KO and DKO served as 
controls. When DNMT3B was removed methylation changes were subtle, yet significant 
according to two-tailed paired t-tests (Figure 2.4). These changes are best evidenced by 
the difference in minimum β values. For example, in parental HCT116 the minimum 
Gene Body β-value is 0.75. In the 3BKO cells, the minimum Gene Body β-value is 0.02. 
Similarly, the minimum 3' UTR β-value in HCT116 is 0.75 compared to 0.09 in 3BKO. 
This trend holds true for shore and shelf methylation. 
 To thoroughly capture the effect of DNMT3B loss on DNA methylation, we 
examined DNA methylation decreases at all genomic signatures that were 
hypermethylated in HCT116 (β values 0.5) and hypomethylated in 3BKO (β values 
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0.2). A total of 314,096 probe positions were hypermethylated in the parental line 
(~6%). At the same position in 3BKO cells, 3,022 probes lost methylation (~1%) (Figure 
2.5 A). Further supporting the notion this demethylation is under the control of 
DNMT3B, β values in 3BKO were very similar to those in DKO cells. Each signature 
had a slight gain in methylation in the 3BKO+WT3B samples not seen in the 
3BKO+MUT3B cells (Figure 2.5 B). These 3,022 demethylated probes corresponded 
with 768 genes. 
Comparison of CpG Island and non-CpG Island DNA methylation  
 Since it is known that DNA methylation patterns can vary significantly between 
CpGs found inside and outside of a CpG island, and these shifts are associated with 
transcriptional changes, methylation levels between the promoter and gene body regions 
were compared. Much is known about the effect of methylation on promoters. Less is 
known about methylation changes in the gene body, and this genomic region was where 
we saw the greatest methylation changes. Interestingly, in our study the larger proportion 
of methylation changes were found in the non-CpG island genes in both promoter and 
gene body regions (Figure 2.6). The loss of DNMT3B seems to have a greater effect on 
the methylation status of non-CpG Island genes compared to CpG Island genes. 
Relationship between DNA methylation and gene expression 
 To correlate DNA methylation changes with transcriptional changes, we 
compared the methylation patterns detected with our available gene expression data. 
Probes with the greatest degree of demethylation in both promoter and gene body regions 
were selected from both CpG categories (CpG island and non-CpG island). A bimodal 
distribution in expression was seen in both genomic regions, independent of CpG status. 
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This suggests the loss of DNMT3B-mediated DNA methylation alone is insufficient in 











Figure 2.1. Transient transfection of wild-type (WT) and mutant (MUT) DNMT3B 
into DNMT3B
-/-
 cells. (A). Mutant DNMT3B (MUT) contains a point mutation in the 
catalytic domain (C651W) which abolishes all DNA methyltransferase activity. (B). A 
DNMT3B
-/-
 cell line was transiently transfected with empty vector alone (3BKO1-3), wild 




Bibikova, M., High density DNA methylation array with single CpG site  
resolution. Genomics, 2011. 98(4): p. 288-295. 
 
Figure 2.2. The Infinium HumanMethylation450 BeadChip Array Platform. Over 
450,000 CpG probes are annotated at discrete functional regions of the human genome. 
The first two signatures are mapped relative to the Transcription Start Site (TSS). 
TSS1500 covers everything from -200 to -1500. TSS200 covers the 200 base pair region 
upstream of the TSS (+1). The 5′ UTR, 1
st
 exon, Gene Body and 3' UTR were also 
















Figure 2.3. Global distribution of DNA methylation upon loss and overexpression of 
DNMT3B according to genomic location. β values closer to 0 = minimal methylation 








Figure 1. Global distribution of DNA methylation upon loss of DNMT3B  
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Figure 2.4. Paired comparison of hypermethylation in parental HCT116  
relative to DNMT3B
-/- 
Cells. A two-tailed paired t-test was used to assess statistical 
significance of differentially methylated regions identified in kernel density plots 






Figure 2.5. Paired Comparison of Hypermethylated Probes in Parental HCT116  
(β values ≥ 0.50) to hypomethylated probes in DNMT3B
-/- 
Cells (β values ≤ 0.2 ). (A) 

































Figure 2.5. Paired Comparison of Hypermethylated Probes in Parental HCT116  
(β values ≥ 0.50) to hypomethylated probes in DNMT3B
-/- 
Cells (β values ≤ 0.2 ). (A) 






Figure 2.6. Identification of genes affected by loss of DNMT3B. Differentially 
demethylated probe distribution according to CpG island status of genomic signatures 
associated with transcriptional regulation. Top panels - CpG Island Genes; Bottom panels 
- non-CpG Island Genes. Black = HCT116, Red = 3BKO, Green = MT1 hypomorph, 
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Figure 2.7. Expression status of genes that correspond with increased probe 
methylation. Genes that corresponded with the most demethylated probes were selected 
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Figure 2.7. Expression status of genes that correspond with increased probe 
methylation. Genes that corresponded with the most demethylated probes were selected 









 Methylation has a complex relationship with gene expression. The most is known 
about DNA methylation dynamics at promoter regions. More than half of human genes 
contain a CpG island, which overlaps the TSS at 60-70% of human genes [6, 26]. When 
located at a TSS, most of these CpG islands are unmethylated.. In regards to CpG 
content, ~72% of promoters have high and 28% have low CpG content [26]. Low CpG 
density regions are frequently located outside of the TSS, suggesting 2 functional classes 
of promoters. When  CpG islands are methylated around the TSS, this blocks the start of 
transcription and is associated with long-term gene silencing. DNA methylation 
dynamics in other genomic regions, and the correlation to gene expression, are currently 
under investigation.  
 Gene body methylation is one such area. This study reported  a subtle loss of 
methylation across the genome upon DNMT3B removal, with the greatest changes 
occurring in Gene Body regions. CpG islands found in gene bodies can be methylated  in 
a tissue-specific manner. By comparison, non-CpG island methylation  is even more 
tissue-specific [6].  Gene body methylation can silence transposable elements but allow 
the host gene to continue transcriptional elongation. It is also know to contribute to 
cancer-causing somatic and germline mutations [6]. From our current understanding, the 
biological role of gene body methylation can vary. Evidence suggests it is a feature of 
transcribed genes. This notion is supported by X-chromosome work, and plant and 
animal shotgun bisulfite sequencing studies [6]. When H3K9me3 and MECP2 are found 
near methylation around the TSS, they repress transcription. However, these epigenetic 
players do not seem  to have the same role at gene bodies. In this setting, transcription is 
not repressed. In fact, it seems gene body methylation promotes transcription elongation, 
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and thus gene activity. Although this study focused on cancer, gene body methylation 
seems to govern normal development as well. Up to 34% intragenic CpG islands are 
methylated in normal brains while the TSS remain largely unmethylated, suggesting 
transcriptional activity. The biological role of such a high degree of methylation remains 
unclear.  
 Gain of methylation lost in a transient DNMT3B overexpression setting was 
unexpected. It is possible DNMT3B may not have been acting alone. Dnmt3a and 
Dnmt3b directly interact via DNMT3L, stimulate each other's activity, and work 
synergistically at target gene promoters [27, 28]. DNMT3L complexes with both 
DNMT3A and DNMT3B to participate in de novo DNA methylation. When DNMT3L 
complexes with particular transcription factors, that can guide a 
DNMT3L/DNMT3A/transcription factor complex to target DNA sequences for 
methylation [29]. Further exploration is needed to determine if DNMT3B has the same 
mechanism in our system. 
 The paramount question is if any genes become silenced or expressed by the loss 
of DNMT3B-dependent methylation. The current model of how DNA methylation relates 
to gene expression would have predicted upregulation of genes that lost methylation in 
the promoter region and downregulation of genes that lost methylation in the gene body. 
The genes that experienced the most CpG island demethylation in the gene body regions 
also correlated with the most upregulation. This exception was also recently reported by 
another lab in cancer cell lines [30]. Perhaps, there is a subset of CpG island genes in the 
gene body that have abundant methylation that correspond with gene repression. This 
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DNMT3B (a de novo DNA methyltransferase) epigenetically regulates gene 





 Human cancers are characterized by aberrant DNA methylation patterns, 
including global hypomethylation and hypermethylation at promoters of tumor 
suppressor genes, leading to transcriptional silencing. The de novo methyltransferases, 
DNMT3A and DNMT3B, establish new methylation patterns. DNMT1, the maintenance 
methyltransferase, ensures propagation of hemi-methylated. Experimentally, DNMT1 is 
capable of transcriptional repression  without its methyltransferase activity, partially 
through interactions with histone-modifying enzymes. We hypothesized DNMT3B may 
also be capable of modulating gene expression independently of its methyltransferase 
activity, by recruiting repressive epigenetic proteins to the promoters of endogenous 
DNMT3B targets. 
  Using an isogenic colorectal cancer cell culture model, we investigated the 
functional consequences of the removal and re-introduction of DNMT3B on target gene 
expression, methylation, and chromatin status. A stable genetic knock out cell line and 
pharmacologic inhibition resulted in upregulation of  candidate DNMT3B targets. 
Interestingly, reintroduction of both wild-type and catalytically dead mutant DNMT3B in 
3BKO cells transcriptionally repressed the same loci. Infinium 450K arrays reported a 
loss of DNMT3B did not result in significant changes in global methylation at TSS, 5' 
UTR, Promoter (-500 --> +1500), CpG Island, and Shore regions. However, significant 
changes were identified in Gene Body, 3' UTR, and Shelf signatures. Overexpression of 
both wild-type and catalytically dead DNMT3B failed to restore DNA methylation.  
 Interestingly, DNMT3B removal had a greater effect on DNA methylation in the 
non-CpG island gene signatures. The lack of basal DNA methylation at the promoters of 
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CpG island genes, in concert with transcriptional repression of these loci, further suggest 
an alternative regulatory mechanism to explain transcriptional changes. DNMT3B was 
recruited back to endogenous target genes and LSD1 recruitment mirrored DNMT3B 
recruitment. Loss of DNMT3B correlated with an increase in an active histone mark 
while a repressive histone mark remained unchanged. Together, this study suggests 
DNMT3B can regulate gene expression in two independent fashions. DNMT3B can 
methylate DNA in a region-specific manner throughout the genome, suggesting C-
terminal domain activity. However, without its catalytic activity, DNMT3B may 







 DNA methylation is essential for controlling normal biological processes like 
mammalian development, X-chromosome inactivation, genomic imprinting, chromatin 
structure, and gene expression. Human cancers are characterized by aberrant DNA 
methylation patterns, such as global hypomethylation and hypermethylation at promoters 
of tumor suppressor genes, leading to transcriptional silencing. Gene expression changes 
can be regulated by enzymes that chemically modify genomic DNA or histones, as well 
as chromatin remodeling factors that regulate chromatin accessibility.  
 DNA methyltransferases are a family of enzymes that catalyze the transfer of 
methyl groups to DNA. DNMT1, the maintenance methyltransferase, has a preference for 
hemi-methylated DNA and ensures the faithful propagation of DNA methylation patterns 
on newly synthesized DNA. The de novo methyltransferases, DNMT3A and DNMT3B, 
establish new methylation patterns during early development. DNMT1 is localized to 
DNA replication foci by UHFR1. DNMT3A and DNMT3B lack a targeting co-repressor 
and  no DNMT recognition site or sequence has been reported to date. 
 All DNMTs share a highly conserved C-terminal catalytic domain, with 
distinctive N-terminal domains. The N-terminal domain is thought to direct nuclear 
localization and interact with other proteins to mediate transcriptional activity. DNMT3B, 
unlike DNMT1 and 3a, is the only DNMT3 with alternatively spliced variants affecting 
the catalytic domain [1]. The specific roles of these variants in cancer are not understood 
but it suggests the catalytic domain may be dispensable for transcriptional regulation. 
 Experimentally, DNMT1 is capable of transcriptional repression  without its 
methyltransferase activity, partially through interactions with histone-modifying enzymes 
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[2]. The study identified endogenous DNMT1 target genes and demonstrated the protein 
represses target genes independent of its catalytic activity. DNA methylation was not 
required for gene repression, even though DNMT1 was recruited back to target promoters 
[2]. When chromatin status was assessed active marks were depleted in the presence of 
both wild type and mutant DNMT1, but repressive marks were unchanged with loss of 
DNMT1 alone [2]. 
 DNMT3B having functions other than the ability to methylate DNA is not 
unheard of. Dnmt3b represses transcription in a methylation-independent manner [3]. 
This may be through the N-terminal domain of DNMT3B which is known to associate 
with  HDAC2 [4]. Tdg and Mbd4 make multiple interactions with Dnmt3b in vivo, with 
reduced T·G mismatch repair efficiency upon loss of DNMT3B [5]. DNMT1, DNMT3B, 
PRC4 components complex together and are targeted to CpG island promoters upon 
oxidative damage [6]. DNMT3B has also been reported to cooperate with DNMT1 to 
maintain methylation in the human genome [7], which is a deviation from its role in early 
development. Thus, it is possible DNMT1 and DNMT3B may operate using similar 
regulatory mechanisms. We hypothesized DNMT3B may also be capable of modulating 
gene expression independently of its methyltransferase activity, by recruiting repressive 
epigenetic proteins to the promoters of endogenous DNMT3B targets. 
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Materials and Methods 
Cell culture  
HCT116, DNMT1
-/- 
hypomorph subclone 5F (MT1KO), DNMT3B
-/-





 subclone 2 (DKO) were previously described [7, 
8]. All cell lines were cultured in McCoy's 5A (Iwakata & Grace Modification) (Cat No. 
10-050-CV, Corning cellgro) supplemented with 10% fetal bovine serum (Cat No. 35-
011-CV, Corning cellgro) at 37 °C and 5% CO2 atmosphere. 
RNA isolation  
RNeasy Mini Kit™ (Cat No. 74104, Qiagen) was used to extract 1 µg total RNA from 
each cell line according to manufacturer's protocol. Isolated total RNA was treated with 
RNase-Free DNase I (Cat No. 79254, Qiagen). 
Gene expression analysis with human gene expression microarrays 
Total RNA was hybridized to Human GE 4x44K v2 Microarray (Cat. No. G4845A, 
Agilent) according to manufacturer's protocol. 
Expression data processing and visualization 
The Bioconductor and Limma packages in the R programming and software environment 
were used to further analyze and visualize expression data. Log2 ratios were calculated. 
Genes with a Log2 ratio of   0.5 were described as upregulated and  -0.5 were 
considered downregulated. 
cDNA synthesis  
One µg total RNA was reversed transcribed using SuperScript III First Strand cDNA 
Synthesis Kit and oligo(dT20) primers (Cat. No. 18080-051, Invitrogen ). For every 20 
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µL prep, 80 µL dd water was added. Five µL of diluted cDNA was used per qPCR 
reaction. Minus RT and water control reactions preps were included. 
Quantitative PCR 
The QuantiTect SYBR Green PCR Kit was used to perform all PCRs (Cat. No. 204243, 
Qiagen). (See Table 3.1 for primers) 
DNMT Inhibitor Treatment 
Parental HCT116 and 3BKO cell lines were both treated with 500 nM 2'-deoxy-5-
azacytidine (DAC) for 72 hours. PBS was used as a mock control. 
Plasmid constructs 
Wild type DNMT3B Isoform 1 (NM_006892.3) with N-terminal HA tag inserts were 
subcloned into a pEF1α IRES-puro vector (WT3B). A QuikChange II Site-Directed 
Mutagenesis Kit (Cat No. 200523, Agilent) was used to generate a catalytically inactive  




 subclone 2 (3BKO) cell line was transiently transfected for 48 hours with 
1 µg of both wild type and mutant plasmid DNA using Lipofectamine 2000 (Cat No. 
11668-027, Life Technologies). 
Genomic DNA isolation 
DNeasy Blood and Tissue Kit™ (Cat No. 69504, Qiagen) was used to extract 1 µg 
genomic DNA from each cell line according to manufacturer's protocol. Isolated genomic 
DNA was bisulfite converted using EZ-DNA Methylation™ Kit (Cat No. D5001, Zymo 




Methylation analysis with the Infinium HumanMethylation450 BeadChip Kit  
DNA methylation analyses of the 9 experimental samples (biological triplicates of 
3BKO, 3BKO overexpressing WT3B, and overexpressing MUT3B) and 3 control cell 
lines (HCT116, MT1KO, and DKO) were performed with the Infinium 
HumanMethylation450 BeadChip Kit (Cat. No. WG-314-1001, Illumina) according to 
the manufacturer’s protocols. The platform contains 486,428 CpG sites distributed across 
the promoter (-500 --> +1500), 5′ UTR, first exon, gene body, 3′ UTR, CpG island, 
shore, and shelf regions and covers 99% of RefSeq genes [9].  
Methylation data processing and visualization 
Illumina GenomeStudio Methylation Module software (Part No. 11319130 Rev. B, 
Illumina) was used to calculate methylation levels and identify methylation signatures 
across the entire genome. Reported β-values reflect the estimated methylation level of 
each CpG locus using the ratio of intensities between methylated and unmethylated 
probes. The Bioconductor package in the R programming and software environment was 
used to further analyze and visualize methylation data. 
Chromatin immunoprecipitation (ChIP) 
Cells were crosslinked using 37 % formaldehyde. Nuclear extracts from ~1 x 10 
6
 cells  
 
were used per IP. Crosslinked cells were resuspended in  CEBN, followed by a CEB  
 
wash. Nuclear pellets were resuspended in SDS lysis buffer. Sonication was performed  
 
using the Bioruptor Pico (Cat No. B01060001, Diagenode). (Program: Time on=30 sec,  
 
Time off=30 sec, Cycle # =40. 60 µg chromatin was used  per IP. Antibodies (2-10 µg):  
 
α-H3K4me3 (Cat No. 07-473, Millipore), α-H3K27me3 (Cat No. 07-449, Millipore), α- 
 





Identification of endogenous DNMT3B target genes. 
 Prior work in our lab has shown Dnmt3b lacking its methyltransferase domain can 
repress transcription of a reporter gene [3]. One drawback to these studies was the 
inability to investigate DNA methylation and chromatin modifications at endogenous 
promoters. We first identified DNMT3B targets using a genetic knockout of DNMT3B 
(3BKO) in HCT116 colorectal cancer cells [3]. In an effort to study the repressive effects 
of DNMT3B, genes that displayed increased expression in the 3BKO setting were 
identified through microarray analysis. In our initial filter, we identified 347 genes 
upregulated ≥0.5 fold in three different 3BKO clones compared to parental HCT116 
(Figure 3.1 A). Next, we sought to determine how many of the 347 candidate genes were 
also upregulated in DKO cells, which lack DNMT3B and contain a DNMT1 hypomorph. 
Of the total 147 genes, 75 known DNMT1 targets were filtered out (Figure 3.1 B). The 
72 remaining DNMT3B target genes were selected for further study. Approximately 2/3 
of the genes were CpG island genes, as expected. Interestingly, ~1/3 were non-CpG 
island genes (Figure 3.1 B).  
 After analyzing microarray date for a subset of target genes (15/72) in various 
DNMT knockout settings, it was clear DNMT1 had a negligible effect on these genes. 
MYC, a gene that is transcriptionally active but not under the control of DNMT3B, served 
as a control (Figure 3.2 A). Quantitative RT-PCR validation showed all genes analyzed 
showed increased expression in 3BKO cells relative to parental HCT116 (Figure 3.2 B). 
To further validate that the genes were DNMT3B specific targets, a DNMT inhibitor was 
used in parental HCT116 and 3BKO cell lines (Figure 3.3). Increase in expression was 
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seen only in HCT116, not 3BKO cells. Thus, depletion of the other DNMTs via 
pharmacologic inhibition in the 3BKO had no effect on target gene expression. 
DNMT3B methyltransferase activity is not required for gene repression 
 To address if the repressive effect of DNMT3B depends on the methyltransferase 
activity of the protein, we overexpressed wild type or catalytically inactive DNMT3B 
into 3BKO cells. The mutant constructs contains a point mutation at amino acid residue 
651. A cysteine to tryptophan substitution abolishes all catalytic activity (previously 
described, see Figure 2.1) without altering the 3-dimensional structure of the DNMT3B 
[10]. An HA tag was added to the N-terminus portion of DNMT3B and the constructs 
were transiently transfected. Western blot analysis indicates robust expression of the two 
DNMT3B species to similar degrees, independent of DNMT3B mutation status (Figure 
2.1). Interestingly, reintroduction of both wild type and catalytically dead DNMT3B in 
the knockout cells transcriptionally repressed most target genes (Figure 3.4). This result 
suggests putting back wild type or mutant DNMT3B both have similar expression 
profiles. Together, these data are consistent with our hypothesis that DNMT3B activity is 
not required for gene repression.   
DNA methylation is not required for gene repression 
 Infinium 450K arrays were used to determine the effects of DNMT3B removal 
and reintroduction on methylation across the genome of the 72 DNMT3B target genes. 
Previous work reported the genetic removal of DNMT3B resulted in a ~3% decrease in 
global genomic methylation [7]. However, the region specificity of that loss could not be 
ascertained due to assay limitations at the time. Methylation arrays afforded the 
opportunity to detect global methylation patterns and region specific changes that can 
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help explain DNMT3B targeting. The methylation status of 8 genomic signatures (TSS, 
5' UTR, Promoter, Gene Body, 3' UTR, CpG Island, Shore, and Shelf) were assessed 
(Figure 2.2).  
 Parental HCT116 was the most hypermethylated cell line used in this study and 
DKO had the least methylation. Single knockout mutants displayed varying degrees of 
methylation. Our focused analysis centered on 3BKO cells. Kernel density revealed 
changes in most regions were minimal (Figure 3.5 A-C, F-G ). In TSS, 5' UTR, Promoter, 
CpG Island, and Shore regions methylation values failed to surpass a density of 3.0 in 
HCT116, reflecting little baseline methylation. Low basal methylation in the parental line 
explains the failure to detect appreciable loss of methylation at these signatures in the 
3BKO cells.  
 Comparatively, Gene Body, 3' UTR, and Shelf regions were more densely 
methylated in HCT116 and displayed decreased methylation in the absence of DNMT3B 
(Figure 3.5 D-E, H). DNA methylation appears to be more prominent and readily lost in 
the areas where transcription is not initiated (Gene Body, 3' UTR, and Shelf regions). 
Overexpression of both the wild type and mutant DNMT3B failed to restore methylation 
in these regions (Figure 3.5 D-E, H). Gene bodies start with much more methylation than 
other genomic regions. Some effect is observed by removing DNMT3B alone. However, 
DNMT1 also has an effect on the methylation of this region. We can surmise that both 
enzymes may be involved with its regulation. This is further evidenced by the complete 
loss of methylation in the DKO cells. Of the 8 genomic regions queried, only 3 had 
noticeable DNA methylation changes in the 3BKO setting. In an effort to test the 
significance of these changes, statistical analyses were performed. Pairwise comparisons 
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were made between differentially methylation regions in parental HCT116 and 3BKO 
cells (Figure 3.6). Changes in methylation are most easily noted by the drop in minimum 
methylation values on the box-and-whisker plots. These regions started with a greater 
amount of basal DNA methylation in HCT116 and showed statistically significant 
decreases in methylation in 3BKO cells according to two-tailed paired t tests. 
Global DNA methylation patterns according to CpG island status 
  Next, we sought to determine if DNA methylation patterns varied at genomic 
regions according to CpG island status. Hypermethylation of CpG islands in promoter 
regions is associated with gene repression, while hypomethylation corresponds with 
transcriptional activity. Although not definitive, the converse is thought to be true for 
CpG islands found in the gene body. A high level of gene body methylation is commonly 
thought to promote transcription.  
 To further elucidate DNMT3B's role in this "DNA methylation paradox", we 
subdivided our 72 DNMT3B target genes into two categories; CpG island (46) and non-
CpG island (26) genes. Loss of DNMT3B has a greater effect on DNA methylation in the 
promoter regions of non-CpG island genes (Figure 3.7 A). This can be explained by a 
greater decrease in median methylation between HCT116 and 3BKO in this population 
when compared to CpG island genes, as depicted by the box-and-whisker plots (Figure 
3.7 B). Similarly, loss of DNMT3B had a greater effect on global DNA methylation 
patterns of non-CpG island genes in gene bodies (Figure 3.8 A). Upon further inspection, 
there is a more significant decrease in minimum methylation values in the 3BKO cells of 
non-CpG island genes when compared to the CpG island genes that may account for most 
changes seen (Figure 3.8 B). These results can be attributed to the fact that non-CpG 
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island genes started with more basal methylation than CpG island genes in both promoter 
and gene body regions.  
 We reasoned by examining all probes associated with a particular DNMT3B 
target gene, that local methylation dynamics across the gene could be more easily 
discernible. A plot of SOX9 shows loss of DNMT3B had a minimal effect on the 
methylation status on this CpG island gene (Figure 3.9 A). At S100A3, a non-CpG island 
gene, loss of DNMT3B resulted in a specific decrease in methylation (Figure 3.9 B). This 
includes a selective loss around the TSS which may account for gene expression changes 
Overexpression of both wild type and mutant DNMT3B failed to restore methylation at 
this gene. This result was expected. Normally a longer time frame is required to see DNA 
methylation changes than the 48 hour period used for this study. To truly assess if these 
local trends are representative for the larger subclasses, further gene-wide 
characterization analysis is necessary.  
 Other data supports the finding that non-CpG island genes experience a specific 
methylation loss due to DNMT3B. When the sum methylation of 26 non-CpG island 
genes at promoter regions were compared with 26 genes randomly selected from the 
genome, the methylation pattern appeared to be specific to DNMT3B target promoters 
(Figure 3.10). The randomly selected genes started with more median methylation overall 
and the loss of DNMT3B had a negligible effect. This study supports the notion that 
DNMT3B influences global DNA methylation patterns according to CpG status. 
Methylation of non-CpG island genes were affected by loss of DNMT3B. However, 
DNMT3B did not seem to play a significant role in methylation of CpG island genes, 
namely at promoters. 
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DNMT3B is recruited back to endogenous target gene promoters 
 In order to better understand the mechanism of repression at CpG island gene loci, 
chromatin immunoprecipitation was performed. The promoter region of DNMT3B target 
genes showed a loss of DNMT3B in the 3BKO setting but increased enrichment for 
DNMT3B after overexpression of wild-type DNMT3B (Figure 3.11 A). LSD1 is a 
histone modifying enzyme known to function as a histone demethylase and 
transcriptional corepressor [11]. Recruitment of LSD1 mirrored that of DNMT3B (Figure 
3.11 B). In support of our hypothesis, this result suggests other repressive epigenetic 
proteins can occupy promoters of DNMT3B target genes. Ongoing studies are being 
performed to determine if mutant DNMT3B can also be recruited back to target 
promoters. Future experiments include studying if these proteins directly interact or occur 
in a larger repressive complex. 
DNMT3B recruitment alters histone modifications at endogenous target gene 
promoters 
 When H3K4me3 is localized to promoter regions it correlates with transcriptional 
activation. Another histone modification, H3K27me3, is associated with a repressive 
chromatin state. Genes that are marked by both are considered bivalent. Bivalent 
chromatin has both activating and repressive epigenetic modifications in the same 
vicinity. We were curious to assess the chromatin status of DNMT3B target genes in the 
presence and absence of DNMT3B. Loss of DNMT3B correlated with  increased 
H3K4me3 at target genes and both wild-type and mutant DNMT3B depleted this mark 
(Figure 3.12). DNMT3B has been associated with genes that harbor repressive 
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H3K27me3 modifications [12]. However, in our study H3K27me3 remain relatively 





















Figure 3.1. Statistical filtering of DNMT3B candidate genes. (A) A total of 347 up-
regulated genes were found in common between stable clones containing an empty vector 
(3BKO #1, 3BKO #2, and 3BKO #3) in a DNMT3B
-/-
 genetic knockout background 
compared to parental HCT116.  All 347 genes shared have a normalized log differential 
expression ratio of ≥0.5. (B) A total of 147 genes were up-regulated in all three 3BKO 
clones and a DKO clone that lacks both  DNMT3B
-/-
 and full length DNMT1
-/-
. Cross 
reference analysis excluded 75 genes up-regulated in a DNMT1
-/-
.  hypomorph clone. 
After exclusion of DNMT1 target genes, 72 DNMT3B candidate genes were selected for 
further analysis. All comparisons were made using a Whitehead Institute for Biomedical 























Figure 3.2. Genetic disruption of DNMT3B in parental HCT116. (A) Microarray 
expression data in various DNMT knockout settings. (B) Quantitative RT-PCR candidate 
gene validation in 3BKO clones compared to parental HCT116. MYC, a gene not under 
the control of DNMT3B serves as a control. Error bars represent the standard error of the 





















Figure 3.3. Pharmacologic inhibition of DNMTs in parental HCT116 and 3BKO 
cells. (A) Quantitative RT-PCR candidate gene expression after a 500 nM DAC treatment 
for 72 hours in HCT116 cells. (B) Quantitative RT-PCR candidate gene expression after 
a 500 nM DAC treatment for 72 hours in 3BKO cells. Samples were then normalized to 
baseline gene expression in parental HCT116. PBS served as the mock negative control 
and SFRP1 was used as a positive control for drug efficacy. Error bars represent the 













Figure 3.4. The effect of wild type and mutant DNMT3B on target gene expression. 
Quantitative RT-PCR candidate gene expression after overexpression of wild type and 
mutant DNMT3B for 48 hours in 3BKO cells. Samples were then normalized to baseline 
gene expression in parental HCT116. Error bars represent the standard error of the mean 































Figure 3.5. Global distribution of DNA methylation upon loss and restoration of 
DNMT3B according to genomic location. Kernel density plots depicting methylation 
values along the x-axis (β values closer to 0 reflect the least methylation 
(hypomethylation) and β values c1oser to 1 reflect the most abundant methylation 
(hypermethylation) at various genomic regions; (A) TSS (B) 5' UTR (C) Promoter (D) 
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Figure 3.6. Paired comparison of  methylation in parental HCT116 relative to 3BKO
 
cells. A two-tailed paired t-test was used to assess statistical significance of differentially 


















Figure 3.7. Methylation patterns according to CpG status at promoters. (A) Global 
distribution of DNA methylation upon loss and restoration of DNMT3B. Kernel density 
plots depicting methylation values along the x-axis (β values closer to 0 reflect the least 
methylation and β values c1oser to 1 reflect the most abundant methylation) at a genomic 
region known to regulate transcriptional control; (Left) CpG island genes (Right) Non-
CpG island genes (Black = HCT116, Blue = 3BKO, Green = MT1 hypomorph, Red = 
DKO). (B) Paired comparisons of  methylation in parental HCT116 relative to 3BKO
 


















Figure 3.8.  Methylation patterns according to CpG status at gene bodies. (A) Global 
distribution of DNA methylation upon loss and restoration of DNMT3B. Kernel density 
plots depicting methylation values along the x-axis (β values closer to 0 reflect the least 
methylation and β values c1oser to 1 reflect the most abundant methylation) at a genomic 
region implicated in transcriptional control; (Left) CpG island genes (Right) Non-CpG 
island genes (Black = HCT116, Blue = 3BKO, Green = MT1 hypomorph, Red = DKO). 
(B) Paired comparisons of  methylation in parental HCT116 relative to 3BKO
 
cells 
















Figure 3.9.  Representative plots of methylation across DNMT3B target genes. (A) 












Figure 3.10. A methylation comparison between non-CpG island DNMT3B targets 
and random genes. (Left) 26 non-CpG island DNMT3B target genes (B) 26 non-CpG 



































Figure 3.11. Repressive protein recruitment to DNMT3B target genes. Analysis of 
ITGB4 and SOX9 promoter regions. Error bars denote standard error of the mean for 





















Figure 3.12. Histone modifications at DNMT3B target genes. Analysis of ITGB4, 
SOX9, and PTGER1 promoter regions. Error bars denote standard error of the mean for 






Table 3.1 qRT-PCR Primer Sequences 
ANXA F CTG GGG CCG CAA TCA GGT GG 
ANXA R TGC GAG CGA AGG TGT CAG CC 
C15orf52 F CCG CGT GAT GGC CAT GTG GT 
C15orf52 R GGG AGG CCA CTC CTT GCC CT 
ESPNL F AGA GTG GAA GCG GCA GGT GAT G 
ESPNL R CCT GAT GAG TCT GTG AGT ACC TC 
FGFBP1 F CCC AGT CAG CCT GGC TCC TGT T 
FGFBP1 R CAT GGC TGC AGC TGG GCG TT 
ID1 F CCG CAA GGT GAG CAA GGT GGA G 
ID1 R CAG GAA CGC ATG CCG CCT CG 
ITGB4 F CCC AGA GCG GGG AGG ACT ACG 
ITGB4 R CTC GAA CTT CCA GCC GCA GCC 
MAGEA6 F CCA GGC TCG GTG AGG AGG CA 
MAGEA6 R CAG GGC AAC AGG CGG GAG TG 
MMP23B F AAG GCG TGT GGC TCA CGG AC 
MMP23B R AGC GTG GCG TTC AGG TGC AT 
PTGER1 F CGC TGG TGT GCA ACA CGC TC 
PTGER1 R GGC CGA AGC GAT GGA CGA GG 
S100A2 F GTC CAG GAT GCC CAG TCC CCA 
S100A2 R TCC CTC CCA GAG AGT GCC AGC 
S100A3 F TCG GGG GCT GGG CAT GTC TC 
S100A3 R GGG CCC CAG AGT GGC TCT ACC 
S100A4 F TCT TCC CCT CTC TAC AAC CCT CTC T 
S100A4 R CAT GAC AGC AGT CAG GAT CAA ACC A 
SH3KBP1 F ACG GCA GGA GAG GTT TGT TCC CT 
SH3KBP1 R GAA TGC CAC CTG GCA CCG GC 
SMPD3 F GAA GCA CAC CTC AGG ACC AAA G 
SMPD3 R CAG CCA GTC CTG AAG CAG GTC 
SOX9 F GTG CAA GCG CCC CCA CTT TT 
SOX9 R GCT ACC GCG GCG AGC ACT TA 
 
Table 3.2 ChIP Primer Sequences 
ITGB4 F1 GAGCTCCTGCTCCATGTTTC 
ITGB4 R1 GGAGTCCCAGTTTGGTTGAA 
SOX9 F GCTCGCTCCAGGCGCGTAAA 
SOX9 R CACTGCTCTCTCCGCGGCAC 
PTGER1 F GGGGGTCACATGGGGCCAGA 





 In this study we report at some endogenous target genes, DNMT3B acts as 
a transcriptional co-repressor independent of its catalytic activity.  
Previous work from our lab and others has shown DNMT3b can repress 
transcription of reporter genes and that the N-terminal domain alone is sufficient 
to facilitate gene repression [3, 13]. The repressive effects of DNMT3B does not 
require enzymatic activity and can be mediated through HDACs [7]. The 
drawback to such studies is it prevents the study of chromatin dynamics at 
endogenous loci. We found that enzymatic activity of DNMT3B was dispensable 
for transcriptional silencing. These changes were associated with loss of DNA 
methylation at non-CpG island genes. By contrast, methylation changes were 
negligible at CpG island genes. At the promoter of some CpG island genes we 
witnessed an increase in active histone marks while repressive histone marks 
remained relatively unchanged.  Gene repression can be mediated through an 
ATRX-like region known as the PHD domain, which is found in many chromatin 
associated proteins. The PHD domain is absent in DNMT1 and only found in the 
DNMT3 protein family. HDAC1 has been reported to directly bind proteins at 
their PHD regions [14]. DNMT3L, which interacts with DNMT3B, lacks a C-
terminal catalytic domain but still exerts transcriptional repression through 
associations with HDACs [14, 15]. In fact, DNMT3B is known to make multiple 
interactions with HDACs [3, 4, 7]. It is possible the PHD domain facilitated the 
repression at DNMT3B target genes identified in this investigation. Further work 
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 The overarching goal of this work was to explore epigenetic mechanisms 
responsible for DNA hypermethylation and gene silencing in cancer. We addressed this 
question by attempting to understand (1) which genomic regions are controlled by 
DNMT3B-mediated DNA methylation and (2) what epigenetic mechanisms govern 
transcriptional repression at DNMT3B target genes after recruitment to endogenous 
promoters. 
 DNA methylation and common regulatory mechanisms are conserved amongst 
most eukaryotic groups, including plants, animals, and insects [1-5]. Under normal 
circumstances, centromeric and repetitive DNA are heavily methylated, promoter regions 
lack methylation, and gene body regions show high levels of methylation. Recent studies 
have specifically implicated the DNMT3 family members as key in modulating DNA 
methylation outside of the promoter in all three model organisms [1, 3]. Due to the 
growing body of literature, we were most curious about the role of DNMT3s in gene 
body methylation.  
 Cancer is hallmarked by aberrant methylation patterns and dysregulation of DNA 
methylation. For our first aim, we tested the hypothesis that DNMT3B may regulate 
DNA methylation patterns at non-promoter genomic regions in cancer. By comparing 
HCT116 (a colorectal cancer cell line) with a derivative cell line 3BKO (genetically 
devoid of both alleles of DNMT3B), we queried 8 genomic signatures for changes in 
DNA methylation. Four regions displayed a statistically significant loss of DNA 
methylation upon DNMT3B removal, and all signatures were distal to the promoter 
(shore, shelf, gene body, and 3' UTR). Overexpression of wild type DNMT3B, but not 
catalytically dead DNMT3B, resulted in a slight gain of methylation. Our data agrees 
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with other labs that gene body regions of cancer cells can retain significant amounts of 
DNA methylation [6]. The fact that DNMT3B seems to somehow influence DNA 
methylation in this region the most raises interesting questions about CpG methylation 
outside of the promoter CpG island context. It is possible that DNMT3B is normally 
bound to these regions. ChIP-Seq studies are the next logical steps towards understanding 
DNMT3B targeting. In specific, this study can be extended further by comparing the 
localization of both wild type and mutant DNMT3B. 
 Prevailing theory states mammalian DNA methylation occurs in the CpG 
dinucleotide context. However, limited studies have revealed significant quantities of 
non-CpG methylation in the genome [7, 8]. Non-CpG methylation is defined as CpA, 
CpT, and CpC. Such non-CpG methylation was found to be more prevalent in human 
embryonic stem cells (15-20%) as opposed to somatic tissues (negligible) [7-9]. The 
functional significance of non-CpG methylation is still undetermined. 
 DNMT1 affected CpG methylation, while Dnmt3a induced CpG, CpA, and CpT 
methylation in vivo using a transgenic Drosophila model [8]. Due to sequence 
similarities, Dnmt3b was not studied. To date, no genome-wide non-CpG assay has been 
been performed looking at DNMT3B targeting. CpG methylation occurs on both strands 
in mammals. However, non-CpG methylated DNA is hemi-methylated. De novo 
methyltransferase activity may explain preferential methylation of non-CpG DNA after 
replication. Research has shown non-CpG methylation disappears during differentiation 
and reappears in induced pluripotent stem cells [7]. For future work, it would be of great 
interest to study how global non-CpG methylation patterns vary in the presence and 
absence of DNMT3B. Non-CpG methylation has been associated with a stem-cell 
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phenotype. Cancers gain hypermethylation at genes that are unmethylated in stem cells, 
have bivalent chromatin, and are reversibly repressed by PRCs. Work from our lab has 
contributed to a model of a stem/progenitor cell signature in cancers [10, 11]. DNMT3B 
could provide interesting new functional clues about this non-traditional methylation in 
cancer. 
 Work has also been done to identify links between non-CpG methylation (around 
the TSS and in the gene body) and gene expression. Similar to CpG methylation, non-
CpG methylation decreased around the TSS and returned to a normal density ~2 kb 
upstream near the 5' UTR. In exons, introns, and 3' UTRs, non-CpG methylation was 
twice as high [7]. At gene bodies, higher expressed genes had 3 times the amount of non-
CpG methylation than genes not expressed [7].  
 We have proven DNMT3B has a distinct set of endogenous target genes in 
colorectal cancer cells and both wild-type and mutant DNMT3B repress target genes. 
DNA methylation at CpG island promoters is not required for this gene repression. 
However, this may be a causative mechanism in non-CpG island genes. DNMT3B and 
LSD1, histone demethylase, can be recruited back to target genes, raising the possibility 
that these loci may be co-regulated. Loss of DNMT3B correlates with an increased active 
histone mark (H3K4me3) at target genes while repressive histone marks remain relatively 
unchanged (H3K27me3). Regulation of DNMT3B target genes seem to involve multiple 
mechanisms according to CpG status. 
 Of note, transiently transfected DNMT3B was tolerated in the somatic cancer cell 
lines used in this study but a stably integrated DNMT3B transgene was not. This suggests 
tight regulation of DNMT3B by cells. Perhaps to prevent further hypermethylation or 
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disrupt regulatory mechanisms allowing for translational control. DNMT3B is also 
known to be selectively expressed in some tissues and has many splice variants in cancer. 
It would be interesting to further investigate how splice variants influence the DNA 
methylation patterns identified in various genomic regions. This would refine the 
molecular underpinning of which DNMT3B domains are necessary for the regulation of 
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